223 related articles for article (PubMed ID: 34224318)
1. Multi-omics landscape of circadian rhythm pathway alterations in Glioma.
Zhang C; Xu J; Chen L; Lin X
Bioengineered; 2021 Dec; 12(1):3294-3308. PubMed ID: 34224318
[TBL] [Abstract][Full Text] [Related]
2. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
3. Serine Incorporator 2 (SERINC2) Expression Predicts an Unfavorable Prognosis of Low-Grade Glioma (LGG): Evidence from Bioinformatics Analysis.
Qi C; Lei L; Hu J; Wang G; Liu J; Ou S
J Mol Neurosci; 2020 Oct; 70(10):1521-1532. PubMed ID: 32642801
[TBL] [Abstract][Full Text] [Related]
4. Identification of potential biomarkers related to glioma survival by gene expression profile analysis.
Hsu JB; Chang TH; Lee GA; Lee TY; Chen CY
BMC Med Genomics; 2019 Mar; 11(Suppl 7):34. PubMed ID: 30894197
[TBL] [Abstract][Full Text] [Related]
5. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
6. Identification of Critical m
Zheng J; Wang X; Qiu Y; Wang M; Yu H; Zhou Z; Wu Z; Jiang X
Biomed Res Int; 2021; 2021():9959212. PubMed ID: 34212046
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of the circadian clock network correlates with tumour progression in gliomas.
Petkovic M; Yalçin M; Heese O; Relógio A
BMC Med Genomics; 2023 Jul; 16(1):154. PubMed ID: 37400829
[TBL] [Abstract][Full Text] [Related]
8. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
Zhao WJ; Ou GY; Lin WW
Front Immunol; 2021; 12():682415. PubMed ID: 34054873
[TBL] [Abstract][Full Text] [Related]
9. Integrative analysis of KIF4A, 9, 18A, and 23 and their clinical significance in low-grade glioma and glioblastoma.
Cho SY; Kim S; Kim G; Singh P; Kim DW
Sci Rep; 2019 Mar; 9(1):4599. PubMed ID: 30872592
[TBL] [Abstract][Full Text] [Related]
10. An integrative multi-omics analysis based on liquid-liquid phase separation delineates distinct subtypes of lower-grade glioma and identifies a prognostic signature.
Zheng J; Wu Z; Qiu Y; Wang X; Jiang X
J Transl Med; 2022 Jan; 20(1):55. PubMed ID: 35093128
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional expression of ZICs as an independent indicator of survival in gliomas.
Han Z; Jia J; Lv Y; Wang R; Cao K
Sci Rep; 2021 Sep; 11(1):17532. PubMed ID: 34475426
[TBL] [Abstract][Full Text] [Related]
12. Expression and prognostic value of microRNAs in lower-grade glioma depends on IDH1/2 status.
Cheng W; Ren X; Zhang C; Han S; Wu A
J Neurooncol; 2017 Apr; 132(2):207-218. PubMed ID: 28091987
[TBL] [Abstract][Full Text] [Related]
13. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
14. Co-amplified with PDGFRA, IGFBP7 is a prognostic biomarker correlated with the immune infiltrations of glioma.
Wang H; Wang X; Xu L; Zhang J
Cancer Med; 2023 Feb; 12(4):4951-4967. PubMed ID: 36043552
[TBL] [Abstract][Full Text] [Related]
15. Survival and low-grade glioma: the emergence of genetic information.
Claus EB; Walsh KM; Wiencke JK; Molinaro AM; Wiemels JL; Schildkraut JM; Bondy ML; Berger M; Jenkins R; Wrensch M
Neurosurg Focus; 2015 Jan; 38(1):E6. PubMed ID: 25552286
[TBL] [Abstract][Full Text] [Related]
16. Expression of CD40 Correlates Negatively with Overall and Progression-Free Survival of Low- and High-Grade Gliomas.
Werner JM; Kuhl S; Ulrich K; Krischek B; Stavrinou P; Goldbrunner R; Timmer M
World Neurosurg; 2019 Oct; 130():e17-e25. PubMed ID: 31125770
[TBL] [Abstract][Full Text] [Related]
17. Exploring the Correlation of Abnormal CXCL9 Expression with Immune Infiltration in Glioma and Patient Prognosis Based on TCGA and GTEx Databases.
Liao Y; Liu B; Jin C; Liao X; Zhang Z
J Mol Neurosci; 2022 Dec; 72(12):2413-2424. PubMed ID: 36449138
[TBL] [Abstract][Full Text] [Related]
18. Selenoprotein GPX1 is a prognostic and chemotherapy-related biomarker for brain lower grade glioma.
Chen X; Fu G; Li L; Zhao Q; Ke Z; Zhang R
J Trace Elem Med Biol; 2022 Dec; 74():127082. PubMed ID: 36155420
[TBL] [Abstract][Full Text] [Related]
19. NAMPT, GRN, and SERPINE1 signature as predictor of disease progression and survival in gliomas.
Vachher M; Arora K; Burman A; Kumar B
J Cell Biochem; 2020 Apr; 121(4):3010-3023. PubMed ID: 31710121
[TBL] [Abstract][Full Text] [Related]
20. The Prognostication Potential of BRCA Genes Expression in Gliomas: A Genetic Survival Analysis Study.
Meimand SE; Pour-Rashidi A; Shahrbabak MM; Mohammadi E; Meimand FE; Rezaei N
World Neurosurg; 2022 Jan; 157():e123-e128. PubMed ID: 34607064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
